Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Pharmacokinetic studies on the selectiveβ 1-receptor antagonist metoprolol in man

Abstract

The pharmacokinetics of 3H-metoprolol, a new selective β 1-receptor antagonist, have been studied in healthy volunteers by following the plasma concentrations and the urinary excretion of the unchanged compound and its total radioactive metabolites after oral and intravenous administration. The compound was rapidly and completely absorbed after oral administration, and about 40% of the dose reached the systemic circulation. The estimated half-life of the absorption process was 10 min. Metoprolol was extensively distributed to extravascular tissues, with the half-life of the distribution phase close to 12 min. About 95% of the dose was excreted in the urine within 72 hr, mainly in metabolized form. The elimination halflife of the compound was close to 3 hr as was also the half-life of the total metabolites after oral administration. After intravenous administration, the elimination half-life of the metabolites was raised to 5 hr, indicating that the route of administra tion might influence the metabolic pathways of the parent compound.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    B. Åblad, E. Carlsson, and L. Ek. Pharmacologic studies of two new cardioselective adrenergic beta-receptor antagonists.Life Sci. 12: 107–119 (1973).

  2. 2.

    M. Rowland. Influence of route of administration on drug availability.J. Pharm. Sci. 61: 70–74 (1972).

  3. 3.

    P. J. Davies and P. Rabinowitz.Numerical Integration, Blaisdell, Waltham, Mass., 1967, p. 22.

  4. 4.

    J. G. Wagner.Biopharmaceutics and Relevant Pharmacokinetics, Drug Intelligence Publications, Hamilton, Ill., 1971, p. 298.

  5. 5.

    N. R. Glass. A technique for fitting nonlinear models to biological data.Ecology 48: 1010–1012 (1967).

  6. 6.

    D. S. Riggs.The Mathematical Approach to Physiological Problems, M.I.T. Press, Cambridge, Mass., 1970, p. 208.

  7. 7.

    J. C. K. Loo and S. Riegelman. Assessment of pharmacokinetic constants from postinfusion blood curves obtained after i.v. infusion.J. Pharm. Sci. 59: 53–55 (1970).

  8. 8.

    M. Gibaldi, R. Nagashima, and G. Levy. Relationship between drug concentration in plasma or serum and amount of drug in the body.J. Pharm. Sci. 58: 193–197 (1969).

  9. 9.

    J. G. Wagner and E. Nelson. Per cent absorbed time plots derived from blood level and/or urinary excretion data.J. Pharm. Sci. 52: 610–611 (1963).

  10. 10.

    J. C. K. Loo and S. Riegelman. New method for calculating the intrinsic absorption rate of drugs.J. Pharm. Sci. 57: 918–928 (1968).

  11. 11.

    D. Perrier, M. Gibaldi, and R. N. Boyes. Prediction of systemic availability from plasmalevel data after oral drug administration.J. Pharm. Pharmacol. 25: 256–257 (1973).

  12. 12.

    D. G. Shand and R. E. Rangno. The disposition of propranolol. I. Elimination during absorption in man.Pharmacology 7: 159–168 (1972).

  13. 13.

    M. Gibaldi, R. N. Boyes, and S. Feldman. Influence of first-pass effect on availability of drugs on oral administration.J. Pharm. Sci. 60: 1338–1340 (1971).

  14. 14.

    S. E. Bradely. InHandbook of Physiology, Sect. II, Vol. II, Williams and Wilkins, Baltimore, 1963, p. 1387.

  15. 15.

    T. Chulski, R. H. Johnsson, C. A. Schlagel, and J. G. Wagner. Direct proportionality of urinary excretion rate and serum level of tetracycline in human subjects.Nature (Lond.) 198: 450–453 (1963).

  16. 16.

    J. G. Wagner. Pharmacokinetics: Notes supplied by John G. Wagner, Ph.D., J. M. Richards Laboratory, Grosse Point Park, Mich., 1969, p. 93.

  17. 17.

    J. G. Wagner.Biopharmaceutics and Relevant Pharmacokinetics, Drug Intelligence Publications, Hamilton, Ill., 1971, p. 261.

  18. 18.

    S. A. Kaplan, M. Lewis, M. A. Schwartz, E. Postma, S. Cotler, C. W. Abruzzo, T. L. Lee, and R. E. Weinfeld. Pharmacokinetic model for chlordiazepoxide-HCl in the dog.J. Pharm. Sci. 59: 1569–1574 (1970).

  19. 19.

    W. J. O'Reilly. Pharmacokinetics in drug metabolism and toxicology.Canad. J. Pharm. Sci. 7: 66–77 (1972).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Regårdh, C.G., Borg, K.O., Johansson, R. et al. Pharmacokinetic studies on the selectiveβ 1-receptor antagonist metoprolol in man. Journal of Pharmacokinetics and Biopharmaceutics 2, 347–364 (1974). https://doi.org/10.1007/BF01061407

Download citation

Key words

  • metoprolol
  • β-receptor antagonist
  • pharmacokinetics
  • disposition